Abstract:
Compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R , R , R , R , A and A have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
Abstract:
Piperidine derivatives, their manufacture and use as medicaments is described. The compounds are useful for treating diseases associated with restenosis, glaucoma, cardiac infarct, high blood pressure and end organ damage, e.g. cardiac insufficiency and kidney insufficiency.
Abstract:
Los compuestos son utiles para el tratamiento de enfermedades que están asociadas con la restenosis, glaucoma, infarto cardíaco, presion sanguínea elevada y lesiones en el organo final. Por ej., insuficiencia cardíaca e insuficiencia renal. Reivindicacion 1: Compuestos de formula (1) en donde R1 es naftilo opcionalmente sustituido por uno a tres grupos alcoxilo C1-5; R2 es fenilo o bencilo, opcionalmente sustituido por sustituyentes seleccionados independientemente entre uno a tres grupos halogeno, ciano, alcoxilo C1-3 y nitro; R3 es H-[CH(OR4)]2-CH2-O-CH2- o R3a-(CH2)k-[CH(OR4)]l-CH2-O-; R3a es hidroxilo o alcoxilo C1-3; R4 es hidrogeno o C1-3-alquilo; k es 1 o 2; l es 1 o 2; y sales farmacéuticamente aceptables de los mismos. Reivindicacion 31: Los compuestos de formula (2) en donde P1 representa un grupo protector de NH usual tal como tert-butoxicarbonilo, benciloxicarbonilo, aliloxicarbonilo, viniloxicarbonilo, alquilsililalquiloxicarbonilo tal como 2-(trimetilsilil)etoxicarbonilo, y tricloroetoxicarbonilo; y R1, R2 y R3 son como se ha definido en la reivindicacion 1.
Abstract:
PCT No. PCT/EP95/04843 Sec. 371 Date Aug. 15, 1997 Sec. 102(e) Date Aug. 15, 1997 PCT Filed Dec. 8, 1995 PCT Pub. No. WO96/19459 PCT Pub. Date Jun. 27, 1996Compounds of the formula: where A, B, R1-R8 are as described herein are endothelin inhibitors that can be used in treating diseases associated with endothelin, such as high blood pressure. Chemical synthesis of these compounds and pharmaceutical compositions containing these compounds are also useful.
Abstract:
Un compuesto de la fórmula (I) (Ver fórmula) donde Rl es piridilo, pirrolilo, imidazolilo, tiazolilo, tiazolinilo u oxazolilo, sustituido opcionalmente con halógeno, alquilo C1-7, hidroxi-alquilo- C1-7 o alquenilo inferior; R2 es R21, -Y-R22 o heterociclilo, donde heterociclilo puede estar opcionalmente mono-, di- o tri-sustituido, independientemente, con hidroxi, alquenilo inferior, amino, alcanoilamino inferior, alcoxicarbonilamino inferior, alquilo C1-7 o hidroxi-alquilo- C1-7; R21 es ciano, hidroxi-alquilo- C1-7, carboxi, -C(O)NRaRb, -(CH2)l-4NHRc, -(CH2)l-4NHC(O)NH(CH2)0-3CH3, amidino, hidroxiamidino, alcoxicarbonilo inferior o hidroxi-alcoxicarbonilo-inferior; R22 es hidrógeno, alcanoilo inferior, carboxialquilo- C1-7, alcoxicarbonilo inferior, alcoxicarbonilo-inferior-alquilo- C1-7, carbamoíl-alquilo- C1-7, di-alquilcarbamoilo- C1-7-alquilo- C1-7, alilo, alquilo C1-7 o hidroxi-alquilo-C1-7; Ra es hidrógeno o alquilo C1-7, sustituido opcionalmente con hidroxi o alcoxi inferior; Rb es hidrógeno o alquilo C1-7; Rc es hidrógeno, acetilo o alquilsulfonilo inferior; X es -CH- o -N-; e Y es -O-, -NH-; y las sales y los ésteres derivados farmacéuticamente aceptables, en donde el término "alquenilo inferior" significa un grupo de alquilo C1-7 conteniendo uno o mas doble(s) enlace(s) en la cadena alquilénica; el término "alcoxi inferior" significa el grupo -O-R'', en donde R'' es un alquilo C1-7, el término "alcanoilo inferior" significa el grupo -C(O)R'', en donde R'' es hidrógeno o alquilo C1-7; el término "heterociclilo" significa un radical carbocíclico insaturado o aromático monovalente de 5 o 6 miembros que tiene por lo menos un heteroátomo; el término "heteroátomo" significa nitrógeno, oxígeno o azufre.
Abstract:
The compounds of formula (I)wherein R1 has the significance as given in the description, are inhibitors of endothelin receptors and can therefore be used for the treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction.
Abstract:
Pyrimidine derivatives have been found to be useful as neuropeptide Y receptor ligands and particularly as antagonists. These pyrimidine derivatives may be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, diabetes, eating disorders, and obesity.
Abstract:
The present invention relates to compound of formula (I) wherein R1 and R2 a re as defined in the description and claims and pharmaceutically acceptable sal ts thereof. The compounds are useful for the treatment of diseases which are associated restenosis, glaucoma, cardiac infarct, high blood pressure and en d organ damage, e.g. cardiac insufficiency and kidney insufficiency.
Abstract:
The compounds of formula (I)wherein R1 has the significance as given in the description, are inhibitors of endothelin receptors and can therefore be used for the treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction.